droxidopa tablets

Functions and indications:
Used for 1. Improve gait stiffness and orthostatic dizziness caused by Parkinson’s disease. 2. Improve orthostatic hypotension, orthostatic dizziness and syncope caused by Shy-Drager syndrome or familial amyloid polyneuropathy. 3. Improve dizziness and fatigue caused by orthostatic hypotension in hemodialysis patients.
Usage and dosage:
Droxidopa capsules: Oral. 1. Improve gait stiffness and orthostatic dizziness caused by Parkinson’s disease. For adults, the usual starting dose is 100 mg once a day, and the dose is increased by 100 mg every other day until the appropriate maintenance dose is reached. The standard maintenance dose is 200 mg each time, 3 times a day. The dose can be increased or decreased according to the patient’s age and symptoms. The daily dose does not exceed 900 mg. 2. Improve orthostatic hypotension, orthostatic dizziness and syncope caused by Shy-Drager syndrome or familial amyloid polyneuropathy. For adults, the usual starting dose is 200-300 mg per day, taken orally in 2-3 times; the dose is increased by 100 mg every few days or 1 week until the appropriate maintenance dose is reached. The standard maintenance dose is 100-200 mg each time, 3 times a day. The dose can be increased or decreased according to the patient’s age and symptoms, and the daily dose does not exceed 900 mg. 3. Improve dizziness and fatigue caused by orthostatic hypotension in hemodialysis patients: Adults usually take 200-400 mg orally 30-60 minutes before hemodialysis. The dose can be reduced according to the patient’s age and symptoms, and the maximum dose does not exceed 400 mg.
Adverse reactions:
1. Serious adverse reactions: (1) Neuroleptic malignant syndrome (<0.1%): high fever, confusion, muscle rigidity, spontaneous movement, elevated direct clear CK, etc. If the above symptoms occur in the early stage of medication, the drug should be discontinued; if it occurs during a dose change or discontinuation of medication during continuous treatment, the previous dose should be restored, followed by a gradual reduction in the dose, and appropriate supportive therapy (such as lowering body temperature, infusion, etc.) should be adopted. (2) Leukopenia (<0.1%), agranulocytosis, neutropenia and thrombocytopenia (frequency unknown): Observe the patient carefully. If abnormal conditions occur, the drug should be discontinued and appropriate supportive therapy should be adopted. 2. Other adverse reactions: See the drug instructions for details. Contraindications: The following is based on foreign literature: 1. The following patients are contraindicated for use of droxidopa: (1) Patients who are allergic to this product. (2) Patients with angle-closure glaucoma (this product can increase intraocular pressure). (3) Patients who inhale halogen-containing anesthetics (such as halothane) (see [Drug-related